Since 2019, cost-effectiveness and budget impact studies performed by our team were used for 32 submissions for inclusion of drugs for treatment of cancer, blood, brain, kidney and other diseases into reimbursement lists. Out of these submissions, 18 drugs were approved for inclusion in the Essential Medicines list and 6 for inclusion in the Federal High-Cost Drugs program.

... by HTA body. This is significantly higher than the average ratings for all submitted proposals – 34.2% for cost-effectiveness and 41.1% for budget impact studies.

This methodology involves mathematical calculations being made by two independent researchers and comparison of their results. If discrepancies arise, the causes are investigated and resolved. This minimizes errors in the modelling process and ensures consistently high quality of our research.

which can emphasize key merits of a product and present them during the economic evaluation. Advanced mathematical modeling techniques are employed for this purpose, allowing the establishment of relationships between key characteristics of drugs for which there is insufficient clinical data.

which is successfully applied today for their promotion after inclusion in the reimbursement lists. This methodology justifies the added value of a new medication to the payer, taking into account relevant critical KPIs established by implemented health programs, eg:

• Population mortality, including specific disease mortality (malignant neoplasms, cardiovascular diseases)
• One-year mortality rate
• Proportion of patients on supervision for 5 or more years
• Life expectancy at birth and other KPIs

We carried out number of disease burden studies, including HIV-infection and chronic viral hepatitis. Through complex mathematical modelling of interrelations between key epidemiologic variables (incidence, prevalence and mortality), we developed additional economic arguments in favor of expanding procurement of modern drugs for patients.